5-nitro-1H-indole-3-carbonyl chloride | 1058740-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-nitro-1H-indole-3-carbonyl chloride
• CAS: 1058740-61-6
• 化学式: C₉H₅ClN₂O₃
• 分子量: 224.603
• InChiKey: BYSTWISJWBBWLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-nitro-1H-indole-3-carbonyl chloride 在 硫酸 、 5%-palladium/activated carbon 、 氢气 、 双氧水 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 15.0h， 生成 methyl 5-[[2-[(4-methoxyphenyl)carbamoylamino]acetyl]amino]-1H-indole-3-carboxylate
  参考文献：
  名称：

  Identification of Small-Molecule Enhancers of Arginine Methylation Catalyzed by Coactivator-Associated Arginine Methyltransferase 1

  摘要：

  Arginine methylation, is a common post-translational modification that is crucial in modulating gene expression at multiple critical. levels. The arginine methyltransferases (PRMTs) are envisaged as promising druggable targets,: but their role in physiological and pathological pathways is far from being clear due to the limited number of modulators reported to date. In this effort; enzyme activators can be invaluable tools, useful as gain-of-function reagents to interrogate the biological roles. in cells and in vivo of PRMTs. Yet the identification such molecule's is rarely pursued. Herein we describe a series of aryl ureido acetamido indole carboxylates (dubbed "uracandolates"), able to increase the Methylation of histone (H3) or nonhistone (polyadenylate-bihding protein 1, PABP1) substrates induced by coactivator-associated arginine methyltransferase 1 (CARM1), bath in in vitro and cellular settings. To the best of our knowledge, this is the first report of compounds acting as CARM1 activators.

  DOI：

  10.1021/jm301097p
• 作为产物：
  描述：

  5-硝基吲哚-3-甲酸 在 草酰氯 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 5-nitro-1H-indole-3-carbonyl chloride
  参考文献：
  名称：

  Novel 5-HT3 antagonists: indol-3-ylspiro(azabicycloalkane-3,5'(4'H)oxazoles)

  摘要：

  The synthesis and biochemical evaluation of a series of spirofused indole oxazoline 5-HT3 antagonists is described in which the oxazoline ring acts as a bioisosteric replacement for esters and amides. The effect of substitution about the indole ring has shown the steric limitations of the aromatic binding site. Incorporation of a variety of azabicyclic systems within the rigid spirofused framework has allowed the definition of a binding model which incorporates a number of known antagonists and agonists. In this model steric constraints limit substitution around the indole ring although there is some bulk tolerance at the 1- and 2-positions. The importance of constraining the basic nitrogen within an azabicyclic system is underlined by comparison with the monocyclic piperidine. The highest affinity was observed for those compounds in which the basic nitrogen occupies a bridgehead position, the most potent analogue in this group being the azabicyclic [3.3.1] system (pIC50 = 8.95), suggesting lipophilic interactions may play a role in increasing affinity. A suggested model for agonist binding is included in which the basic nitrogens are superimposed and the 5-hydroxyl group of 5-HT is superimposed on the H-bond-accepting atom of the heterocyclic linking group.

  DOI：

  10.1021/jm00084a007

文献信息

• Antibacterial therapeutics and prophylactics
  申请人：VYOME BIOSCIENCES PVT. LTD.

  公开号：US10570152B2

  公开（公告）日：2020-02-25

  The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

  本公开内容一般涉及用于治疗细菌感染的新型分子、组合物和制剂，更具体地说，涉及具有抗生素耐药性病原体的细菌感染。
• [EN] ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS<br/>[FR] AGENTS THÉRAPEUTIQUES ANTIBACTÉRIENS ET AGENTS PROPHYLACTIQUES
  申请人：VYOME BIOSCIENCES PVT LTD

  公开号：WO2017017631A3

  公开（公告）日：2017-04-06
• ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS
  申请人：Vyome Biosciences Pvt. Ltd.

  公开号：EP3328856A2

  公开（公告）日：2018-06-06